Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2006

Conditions
Bipolar Depression
Interventions
DRUG

Uridine

Trial Locations (11)

10023

Medical & Behavioral Health Research, PC, New York

20852

Marc Hertzman, MD, PC, Rockville

30080

Carman Research, Smyrna

44195

Cleveland Clinic Foundation, Cleveland

45267

University of Cincinnati, Cincinnati

46202

Indiana University-Purdue University Indianapolis, Indianapolis

75231

Future Search Trials of Dallas, Dallas

78229

University of Texas Health Science Center at San Antonio, San Antonio

78756

Future Search Trials of Austin, Austin

94305

Stanford University, Stanford

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Repligen Corporation

INDUSTRY

NCT00322764 - Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression | Biotech Hunter | Biotech Hunter